Alzheon Appoints Three Industry And Alzheimer’s Leaders To Board Of Directors
1/8/2014 8:19:39 AM
Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that it has appointed Menghis Bairu, MD, Franklin Berger and Scott Minick to the company’s Board of Directors. Each of these new Board members brings more than 25 years of strategic and management experience in the biotechnology industry as well as unique Alzheimer’s drug development expertise to support Alzheon’s growth as a leading Alzheimer’s company.
Help employers find you! Check out all the jobs and post your resume.